Kling Bio Validates its Proprietary B-Cell Technology for Rapid Response Against Emerging Viral Variants

/in

Study demonstrated the use of immortalized B-cell libraries as a rapid and adaptable approach to therapeutic development against evolving viral threats Discovered 12 antibodies with potent neutralizing activity against multiple SARS-CoV-2 strains, including Delta and BA.5, through high-throughput B-cell screening Applied ex vivo directed evolution to B-cell clones to enhance antibody neutralizing breadth and potency […]

Read more

Results from BIG D-FOOT study using STIMULAN® when treating DFO to be presented at EBJIS 2025

/in

Randomised, double-blinded, controlled BIG D-FOOT study demonstrates that local antibiotic delivery using STIMULAN® significantly reduces post-surgical infective complications in patients with diabetic foot osteomyelitis (DFO) Biocomposites symposium will explore best practice treatment strategies for complex infections and share findings from the BIG D FOOT study Keele, UK, 9 September 2025 – Biocomposites, an international medical […]

Read more

DeuterOncology to Present Promising Phase I DO-2 MET Kinase Inhibitor Data at WCLC 2025

/in

DO-2 is a best-in-class MET kinase inhibitor that has completed enrollment in a Phase 1 dose escalation study Tumor shrinkage was observed in 100% of MET exon 14 skip NSCLC patients without additional oncogenic drivers, at doses that achieved preclinically defined thresholds DO-2 has a very good safety profile with minimal peripheral oedema and clean […]

Read more

CONNECTA Therapeutics to Advance CTH120 into Phase II Pediatric Development for Fragile X Syndrome with EIC Accelerator Support

/in

CTH120 is a first-in-class neuroplasticity modulator with strong Phase I safety and tolerability data Awarded a €2.5M European Innovation Council (EIC) Accelerator grant to prepare for Phase II development in pediatric Fragile X Syndrome (FXS) patients CONNECTA leads innovation in neurodevelopmental therapies as a unique European biotech advancing a clinical-stage FXS program Barcelona, Spain – […]

Read more

Pheon Therapeutics Bolsters Board of Directors with Oncology R&D Expert Dr. Samuel Blackman

/in

Dr. Blackman is an Entrepreneur-in-Residence at Google Ventures and a former senior pharma executive with a track record of leading the development of innovative cancer therapies  Oncology expertise spans proof-of-biology studies, biomarker development, and clinical-stage decision-making from first-in-human studies through approval London, UK, 9 September 2025 – Pheon Therapeutics (Pheon), a clinical-stage leading Antibody-Drug Conjugate […]

Read more
© Optimum Strategic Communications.